The role of ERBB2 in cancer progression is well established (reviewed in [1,5]) and targeting ERBB2 through specific monoclonal antibodies, such as trastuzumab and pertuzumab, represents the gold standard to treat HER2-positive breast cancer patients in clinics (reviewed in [1]). Here, ERBB2 is linked to breast cancer.